Analyst consensus rating
Aptevo Therapeutics Analyst Rating: none
Direct answer
Aptevo Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.50.
Forecast evidence checked October 27, 2026.
Get free Aptevo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.28
- Average price target
- $25.50
- High price target
- $30.00
- Low price target
- $21.00
- Low target gap
- +1,540.6%
- Target upside
- +1,892.2%
- High target gap
- +2,243.8%
- Target range width
- 703.1%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aptevo Therapeutics?
Aptevo Therapeutics has a verified none consensus. The same dataset has an average price target of $25.50.
How far are Aptevo Therapeutics's low and high targets from the recorded price?
The low target implies +1,540.6%, while the high target implies +2,243.8%.
How many analysts are included in Aptevo Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Aptevo Therapeutics's target upside or downside calculated?
The average target of $25.50 is divided by the recorded price of $1.28, then one is subtracted to produce +1,892.2%. This does not guarantee a future return.
When was Aptevo Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.